Publication | Closed Access

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Hematological MalignancyOncologyMetronomic TherapyHematologyClinical TrialsPharmacologyMyeloid NeoplasiaPharmacotherapyLow-dose DexamethasoneMedicinePhase 3Refractory Multiple MyelomaHealth Sciences